Amarin Corp Plc (AMRN)

[zumantu]

Chas, one factor that gets glossed over, but that I see repeatedly described and illustrated in Amarin patent applications is the synergistic effect of Statin on EPA's antioxidant power. In fact they mention this in the investor presentation . In patents it's illustrated as greater reduction of Hydroperoxides by the combination of EPA and Statin vs either alone.
So on my mind, there is a therapeutic effect not yet accounted for in our analysis that comes from higher Statin dose in which the power of EPA is increased, and thus giving the treatment arm a boost - a boost in addition to what we think of as plasma EPA levels

I can't predict the affect, but literature suggests it indeed exists